Hypertrophic Cardiomyopathy (HCM) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
Hypertrophic cardiomyopathy (HCM) is a genetic disorder affecting cardiac myocytes, characterized by cardiac hypertrophy, which loading conditions cannot explain, a nondilated left ventricle, and a normal or increased or increased ejection fraction. Cardiac hypertrophy is typically asymmetric and commonly involves the basal interventricular septum subjacent to the aortic valve, although other myocardial regions may also be affected. At the cellular level, cardiac myocytes are hypertrophied, disorganized, and separated by areas of interstitial fibrosis. Most patients with HCM are asymptomatic or have minimal symptoms. However, the condition can cause a range of pathophysiological features, including diastolic ventricular dysfunction, obstruction to the left ventricular outflow tract, an imbalance between myocardial oxygen supply and demand, and cardiac arrhythmias. Patients with HCM may exhibit a variable phenotype, with ventricular hypertrophy being the cardinal manifestation and myocyte hypertrophy, disarray, interstitial fibrosis, impaired ventricular filling, and dynamic left ventricular outflow tract obstruction. Clinical diagnosis of HCM is based on left ventricular hypertrophy, typically defined by an end-diastolic ventricular septal thickness in adults of 13 mm or greater, occurring without abnormal loading conditions or other secondary causes. HCM is a common cause of sudden cardiac death in adolescents and young adults, particularly in competitive athletes.
· The prevalence of HCM has been estimated at 0.16% to 0.29% (≈ 1:625–1:344 individuals) in the general adult population.
Thelansis’s “Hypertrophic Cardiomyopathy (HCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypertrophic Cardiomyopathy (HCM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hypertrophic Cardiomyopathy (HCM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hypertrophic Cardiomyopathy (HCM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
